About this trial
The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology settings. Patients will be invited to participate in this study by having non-dilated photos of their eyes taken by an FDA approved fundus camera (DRSPlus from Centervue Inc., CA), at their primary care doctor's office or general ophthalmologist office. The photos will then be transmitted securely and analyzed by computer in the cloud (telemedicine features). Sufficient accuracy of the automatic system has been established compared to the ophthalmologist's diagnosis. In this study, we aim to validate the system against the prospectively taken OCT image and color fundus images.
Eligibility criteria
Qualifiers
Subjects will be recruited if willing and able to comply with clinic visit and study-related procedures, and provide signed informed consent
Disqualifiers
Already diagnosed with AMD, unable to provide informed consent and currently under treatment of retinal disease.
Trial design
Treatments tested in this trial
- No intervention.
Treatment groups
Sponsors and collaborators
iHealthScreen Inc
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Eye Institute (NEI)
Collaborator